Biohaven Pharmaceutical said on May 23 the company’s experimental drug for patients with spinocerebellar ataxia, a genetic disease that affects the nervous system, failed to meet the main goal of a late-stage study.
Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders
Alzheimer’s Disease, Amyotrophic Lateral Sclerosis (ALS), Biotechnology, Central Nervous System, CNS Disorders, Collaboration, Duchenne Muscular Dystrophy (DMD), Frontotemporal Dementia (FTD), Genes, Huntingtin (HTT) Gene, Huntington’s disease, Issue Archives, Parkinson’s disease, Spinocerebellar Ataxia Type 3 (SCA3)Wave Life Sciences Ltd. announced the formation of a global strategic collaboration with Takeda Pharmaceutical Company Ltd. to discover, develop and commercialize nucleic acid therapies for disorders of the central nervous system.